Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Biotechnology

Pharnext

Pharnext's headquarters in Issy-les-Moulineaux, France

Hugo Brugière

Vincent Serra

Kévin Scialom

Gilbert Wagener

Serguei Nabirotchkine, PhD

Raj Thota

Lawrence Steinman

James Kuo

Description

People (1)

Serguei Nabirotchkine, PhD